Skip to main content
. 2014 May 22;15(5):9160–9172. doi: 10.3390/ijms15059160

Figure 4.

Figure 4.

Ki-67 labeling index and immunohistochemistry of 4-NQO-induced pulmonary proliferative lesions from mice treated with or without fenofibrate. (A) Representative features of Ki-67 immunohistochemistry in a mouse treated with 4-NQO alone (upper; group 1) or 4-NQO followed by 0.01% fenofibrate (lower; group 2). Bars = 20 μm; (B) Dietary administration of 0.01% fenofibrate significantly lowered the Ki-67 labeling index in group 2 compared with mice treated with 4-NQO alone (group 1) (p < 0.05).